Dose comparison trial of sustained-release fampridine in multiple sclerosis

Neurology

Volumn 71, Issue 15, 2008, Pages 1134-1141

  Goodman, A D ^a   Brown, T R ^b   Cohen, J A ^c   Krupp, L B ^d   Schapiro, R ^e   Schwid, S R ^a   Cohen, R ^f   Marinucci, L N ^f   Blight, A R ^f  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Evergreen Hospital Medical Center   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^e Minneapolis Clinic of Neurology   (United States)

^f ACORDA THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARTICLE; ASTHENIA; BALANCE DISORDER; BLURRED VISION; BONE STRENGTH; CANADA; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION DISORDER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FATIGUE; FOOT; HUMAN; INSOMNIA; LEG; MAJOR CLINICAL STUDY; MENTAL HEALTH; MOBILIZATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; OUTCOME ASSESSMENT; PAIN; PARALLEL DESIGN; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEIZURE; SELF EVALUATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SUSTAINED DRUG RELEASE; THORAX PAIN; TONIC CLONIC SEIZURE; TREATMENT DURATION; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WALKING SPEED; ADOLESCENT; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DISABILITY; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; WALKING;

4-AMINOPYRIDINE; ADOLESCENT; ADULT; AGED; DELAYED-ACTION PREPARATIONS; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS; TREATMENT OUTCOME; WALKING;

EID: 52949133688     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000326213.89576.0e     Document Type: Article

References (37)

1. Lechat P, Thesleff S, Bowman WC. Aminopyridines and Similarly Acting Drugs, Effects on Nerves, Muscles and Synapses. Oxford: Pergamon Press, 1982.
2. Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-259.
3. Pencek TL, Schauf CL, Low PA, Eisenberg BR, Davis FA. Disruption of the perineurium in amphibian peripheral nerve: morphology and physiology. Neurology 1980;30: 593-599.
4. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibers. J Physiol (Lond) 1981;313:301-315.
5. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358-361.
6. Kaji R, Sumner AJ. Effects of 4-aminopyridine in experimental CNS demyelination. Neurology 1988;38:1884-1887.
7. Blight AR. Effect of 4-aminopyridine on axonal conduction block in chronic spinal cord injury. Brain Res Bull 1989;22:47-52.
8. Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77: 553-562.
9. Coetzee WA, Amarillo Y, Chiu J, et al. Molecular diversity of K+ channels. Ann NY Acad Sci 1999;868:233-285.
10. Mainero C, Inhilleri M, Pantano P, et al. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology 2004;62:2044-2050.
11. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:353-362.
12. Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21:71-77.
13. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-192.
14. Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-1348.
15. van Diemen HAM, Polman CH, van Dongen TMMM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32:123-130.
16. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-Aminopyridine in the treatment of patients with multiple sclerosis, long term efficacy and safety. Arch Neurol 1994;51:292-296.
17. Polman CH, Bertelsmann FW, de Waal R, et al. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994;51:1136-1139.
18. Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44:1054-1059.
19. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-821.
20. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-368.
21. van Diemen HAM, Polman CH, Koetsier JC, van Loenen AC, Nauta JJP, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharm 1993;16:195-204.
22. Lundh H, Nilsson O, Rosén I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 1979; 42:171-175.
23. Ball AP, Hopkinson RB, Farrell ID, et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979;48:473-491.
24. Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:265-271.
25. Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980;16:487-497.
26. Hayes KC, Katz MA, Devane JG, et al. Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal patients and patients with spinal cord injury. J Clin Pharmacol 2003;43:379-385.
27. Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in patients with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004;85:29-34.
28. Fischer JS, Jak AJ, Kniker JE, Rudicke RA, Cutter G. Multiple Sclerosis Functional Composite (MSFC): Administration and Scoring Manual. Available at: http://www.nationalmssociety.org.
29. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-542.
30. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999;5:251-259.
31. Hobart J, Riazi A, Lampling D, Fitzpatrick R, Thompson A. Measuring the impact of MS on walking ability. J Neurol 2003;60:31-36.
32. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
33. Medical Research Council. Aids to the investigation of peripheral nerve injuries, War Memorandum Number, 2nd ed. London: His Majesty's Stationery Office, 1943.
34. Kragt JJ, van der Linden FAH, Nielsen JM, Uitdehaag BMJ, Polman CH. Clinical impact of 20% worsening on Timed 25-Foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult Scler 2006;12:594-598.
35. Ghezzi A, Montanini R, Basso PF, Zaffaroni M, Massimo E, Cazzullo CL. Epilepsy in multiple sclerosis. Eur Neurol 1990;30:218-223.
36. Spatt J, Chaix R, Mamoli B. Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol 2001;248:2-9.
37. Poser CM, Brinar VV. Epilepsy and multiple sclerosis. Epilepsy Behav 2003;4:6-12.